Public health issues have been raised regarding fructose toxicity and its serious metabolic disorders. Deleterious effects of high fructose intake on insulin sensitivity, body weight, lipid homeostasis have been identified. The new millennium has witnessed the emergence of a modern epidemic, the metabolic syndrome (MS), in approximately 25% of the world’s adult population. The current study aimed to investigate the effect of the TNF-α antagonist infliximab on fructose-induced MS in rats. Rats were administered fructose (10%) in drinking water for 12 weeks to induce the experimental MS model. infliximab (5 mg/kg) was injected once weekly intraperitoneally starting on the 13th week for 4 weeks. Increase in body weight, blood glucose level, serum triglycerides (TGs), adiponectin level and blood pressure were present in MS rats. They also prompted increases in serum of leptin, TNF-α, and malondialdehyde (MDA) levels. Treatment with infliximab did not affect body weight, hyperglycemia or hypertension, but decreased serum TGs and increased serum HDL-c levels. Infliximab also decreased adiponectin levels. Surprisingly, infliximab increased MDA above its value in the MS group. These results reflect the fact that infliximab affects the manifestations of MS in rats. Though infliximab reduced TGs, increased HDL-c levels, reversed adiponectin resistance occurred by fructose, the drug failed to combat MS-mediated hyperglycemia, hypertension, and elevated MDA above the insult.

果糖毒性及其严重的代谢紊乱引起了公共卫生问题。已经确定高果糖摄入对胰岛素敏感性、体重、脂质稳态的有害影响。新千年见证了现代流行病——代谢综合征 (MS) 的出现，约占世界成年人口的 25%。目前的研究旨在研究 TNF-α 拮抗剂英夫利昔单抗对大鼠果糖诱导的 MS 的影响。大鼠在饮用水中施用果糖 (10%) 12 周以诱导实验性 MS 模型。从第 13 周开始，每周一次腹膜内注射英夫利昔单抗 (5 mg/kg)，持续 4 周。MS 大鼠的体重、血糖水平、血清甘油三酯 (TG)、脂联素水平和血压均增加。它们还促使血清瘦素、TNF-α 和丙二醛 (MDA) 水平升高。英夫利昔单抗治疗不会影响体重、高血糖或高血压，但会降低血清 TG 和增加血清 HDL-c 水平。英夫利昔单抗还降低了脂联素水平。令人惊讶的是，英夫利昔单抗将 MDA 增加到高于其在 MS 组中的值。这些结果反映了英夫利昔单抗影响大鼠 MS 表现的事实。尽管英夫利昔单抗降低了 TG，增加了 HDL-c 水平，逆转了果糖引起的脂联素抵抗，但该药物未能对抗 MS 介导的高血糖、高血压和高于损伤的 MDA 升高。英夫利昔单抗还降低了脂联素水平。令人惊讶的是，英夫利昔单抗将 MDA 增加到高于其在 MS 组中的值。这些结果反映了英夫利昔单抗影响大鼠 MS 表现的事实。尽管英夫利昔单抗降低了 TG，增加了 HDL-c 水平，逆转了果糖引起的脂联素抵抗，但该药物未能对抗 MS 介导的高血糖、高血压和高于损伤的 MDA 升高。英夫利昔单抗还降低了脂联素水平。令人惊讶的是，英夫利昔单抗将 MDA 增加到高于其在 MS 组中的值。这些结果反映了英夫利昔单抗影响大鼠 MS 表现的事实。尽管英夫利昔单抗降低了 TG，增加了 HDL-c 水平，逆转了果糖引起的脂联素抵抗，但该药物未能对抗 MS 介导的高血糖、高血压和高于损伤的 MDA 升高。